Results 131 to 140 of about 62,277 (245)

Monitoring of Blood Clozapine Levels After a Change in Smoking Status for Patients Treated With Clozapine: A Clinical Audit From Hull Community Mental Health Team

BJPsych Open
Aims According to The Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update in August 2020 regarding clozapine, monitoring blood clozapine levels for toxicity is now advised in certain clinical situations such as when a patient ...
Kamran Mahmood, Odira Anakebe, Keshia Theobalds-Ward, Madhu Gulati   +3 more
doaj   +1 more source

Heartfelt intervention: A role for PVN oxytocin neurons in the prediabetic heart

The Journal of Physiology, EarlyView.
Grace K. Nielsen, Reesa M. Wilcox, Han‐Jun Wang   +2 more
wiley   +1 more source

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent
Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura   +2 more
wiley   +1 more source

Combined Inhibition of TRPM4/NMDA Receptor Complex and Extrasynaptic NMDA Receptors Is Candidate Therapeutic Target for Suppression of Epileptic Seizures and Improvement of Cognitive Impairments

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Cognitive impairments are important therapeutic targets in epilepsy medication; however, effective pharmacological treatments for epilepsy patients with comorbid cognitive impairment have not been established. Effects of chronic administration of MK‐801 (noncompetitive NMDA receptor inhibitor), memantine (low‐affinity extrasynaptic‐NMDA ...
Motohiro Okada, Ruri Okubo, Tomoka Oka, Eishi Motomura   +3 more
wiley   +1 more source

A psychiatric medication, clozapine, induces autophagy and apoptosis in breast cancer cells through reactive oxygen species.

PLoS ONE
Cancer patients with psychotic disorders have occasionally exhibited reduced tumor sizes following long-term antipsychotic treatment. Previous studies have shown that antipsychotic drugs, such as clozapine, could inhibit cancer cell proliferation, but ...
Ya-Chun Fan, Shih-Chao Lin, Po-Jung Lai, Pei-Chun Lai, Germain Maurus, Shiow-Yi Chen   +5 more
doaj   +1 more source

Involuntary Clozapine Treatment: A Systematic Review

Acta Psychiatrica Scandinavica, Volume 153, Issue 6, Page 595-609, June 2026.
ABSTRACT Introduction We aimed to synthesize the information relevant for clinical practice on involuntary clozapine treatment. Methods Articles were identified with MEDLINE, Web of Sciences and PsycINFO search from inception through September 2025 (PROSPERO database registration CRD420251234475).
Hélène Verdoux, Alexis Lepetit, Peter F. J. Schulte   +2 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1287-1308, May 2026.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

Predictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia.

PLoS ONE
Clozapine has superior efficacy to other antipsychotics, especially in patients with treatment-resistant schizophrenia. However, its pharmacokinetics and pharmacodynamics vary largely among patients.
Sang-In Park, Seoyoung Kim, Kwanwoo Park, Uijeong Yu, Yunjeong Jang, Bo-Hyung Kim, Ji Hyun Lee, Euitae Kim   +7 more
doaj   +1 more source

Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1331-1339, May 2026.
Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic ...
Kaio Evandro Cardoso Aguiar, Natasha Monte da Silva, Juliana Carla Gomes Rodrigues, André Maurício Ribeiro‐dos‐Santos, Sandro José de Souza, Ândrea Ribeiro‐dos‐Santos, João Farias Guerreiro, Sidney Emanuel Batista dos Santos, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos   +9 more
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source